Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter Study to Evaluate the Long-term Safety of Weekly Intravenous Alpha1-Proteinase Inhibitor (Human), Modified Process 60 mg/kg in Subjects With Pulmonary Emphysema Due to Alpha1-Antitrypsin Deficiency

NCT02796937 is registered in ClinicalTrials.gov with Grifols Therapeutics LLC as lead sponsor.

NCT NCT02796937
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02796937 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter Study to Evaluate the Long-term Safety of Weekly Intravenous Alpha1-Proteinase Inhibitor (Human), Modified Process 60 mg/kg in Subjects With Pulmonary Emphysema Due to Alpha1-Antitrypsin Deficiency
Lead sponsor
Grifols Therapeutics LLC
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
July 31, 2016
Completion date
February 28, 2029
Enrollment
290 (estimated)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary emphysema in alpha-1 antitrypsin deficiency